- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| OS THERAPIES Aktie jetzt für 0€ handeln | |||||
| Fr | OS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11:00am EDT | 213 | Newsfile | New York, New York--(Newsfile Corp. - September 19, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate... ► Artikel lesen | |
| 12.09. | OS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last Visit | 246 | Newsfile | Clinical data from Phase 1b prostate cancer trial to be released in Q4/25Additionally, updated 2-year overall survival data from all 40 patients in the Phase 2b clinical trial of OST-HER2 in the prevention... ► Artikel lesen | |
| 03.09. | OS Therapies to Participate in Upcoming Investor Conferences in September 2025 | 254 | Newsfile | New York, New York--(Newsfile Corp. - September 3, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate... ► Artikel lesen | |
| 02.09. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 02.09. | OS Therapies Provides OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Program Update Following FDA End of Phase 2 Meeting | 260 | Newsfile | Company on track to begin submission of a rolling Biologics Licensing Application (BLA) request for OST-HER2 to U.S. Food & Drug Administration in September 2025 New York, New York--(Newsfile Corp.... ► Artikel lesen | |
| 02.09. | OS Therapies Completes Exercise Inducement and Exchange Offer for All Remaining Outstanding Warrants Issued in Connection with December 2024 Financing | 392 | Newsfile | All remaining holders of outstanding warrants with $1.12 per share exercise price have participated, raising $3.7 million in gross proceeds to be used to accelerate OST-HER2 commercial launch preparationsNew... ► Artikel lesen | |
| 27.08. | OS Therapies to Provide OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma FDA End of Phase 2 Meeting Update on Tuesday, September 2, 2025 | 320 | Newsfile | New York, New York--(Newsfile Corp. - August 27, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate... ► Artikel lesen | |
| 26.08. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 26.08. | OS Therapies Terminates Equity Line of Credit | 360 | Newsfile | New York, New York--(Newsfile Corp. - August 25, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate... ► Artikel lesen | |
| 19.08. | OS Therapies reports Q2 results | 10 | Seeking Alpha | ||
| 19.08. | OS Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update | 476 | Newsfile | U.S. FDA ("FDA") confirms OST-HER2 meets biological definition of Regenerative Medicine Advanced Therapy (RMAT) FDA issues OST-HER2 BLA number in preparation for Accelerated Approval submission following... ► Artikel lesen | |
| 18.08. | OS Therapies Inc - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 18.08. | Earnings Outlook For OS Therapies | 1 | Benzinga.com | ||
| 15.08. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 14.08. | OS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025 | 383 | Newsfile | New York, New York--(Newsfile Corp. - August 14, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate... ► Artikel lesen | |
| 08.08. | OS Therapies files $100M mixed securities shelf | 1 | Seeking Alpha | ||
| 07.08. | OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma | 202 | Newsfile | 66.6% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p = 0.0046)FDA issues Biologics Licensing Application (BLA) number for OST-HER2... ► Artikel lesen | |
| 07.08. | OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma | 246 | Newsfile | MHRA seeks to harmonize UK & US regulatory review via Project OrbisEMA Rapporteur Scientific Advice Meeting scheduled for October 2025New York, New York--(Newsfile Corp. - August 7, 2025) - OS Therapies... ► Artikel lesen | |
| 04.08. | OS Therapies Inc - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 14.07. | OS Therapies Inc - 8-K, Current Report | 4 | SEC Filings |
1 2 3 Weiter >>
52 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 53,50 | +1,90 % | CRISPR Therapeutics AG: CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe | ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based... ► Artikel lesen | |
| IMMUNIC | 0,738 | -1,47 % | EQS-News: Immunic AG: Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis | Issuer: Immunic AG
/ Key word(s): Patent
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 2,200 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series | King of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 7,298 | +1,56 % | Anavex Life Sciences Corp.: Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer's Disease Trial | New clinical Precision Medicine population 48-week data demonstrates unprecedented cognitive stabilization in early Alzheimer's disease Cognitive outcomes observed in the oral blarcamesine 30 mg Precision... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 20,490 | 0,00 % | Cathie Wood's ARK ETF adjusts holdings, ARCT and TEM in focus | ||
| PROTALIX BIOTHERAPEUTICS | 1,730 | -1,70 % | Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics to Present at Investor Summit Virtual | CARMIEL, ISRAEL / ACCESS Newswire / September 11, 2025 / Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 7,950 | +3,92 % | Zevra Therapeutics: Zevra Reports Second Quarter 2025 Financial Results and Corporate Update | Q2 2025 net revenue of $25.9 million, driven by product net revenue of $21.8 million Completed sale of PRV for $150.0 million, bolstering the balance sheet as the Company executes on its commercial... ► Artikel lesen | |
| GEOVAX LABS | 2,685 | -100,00 % | GeoVax Labs: Strategische Impfstoff-Entwicklungen und Finanzierungspläne vorgestellt | ||
| SCILEX | 28,380 | 0,00 % | Scilex Holding Company Announces It Has Entered into a Memorandum of Understanding with Biconomy.com to Collaborate on Future Cryptocurrency Strategies and Treasury Management | PALO ALTO, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and... ► Artikel lesen | |
| MEIRAGTX | 6,700 | -4,96 % | MeiraGTx Reports Second Quarter 2025 Financial and Operational Results | - Gained alignment with U.S. Food and Drug Administration (FDA) on the ongoing Phase 2 AQUAx2 randomized double-blind, placebo-controlled pivotal study in Grade 2/3 radiation-induced xerostomia (RIX)... ► Artikel lesen | |
| TENAYA THERAPEUTICS | 1,560 | 0,00 % | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially... ► Artikel lesen | |
| INVIVYD | 1,210 | 0,00 % | Invivyd, Inc. - 8-K, Current Report | ||
| UNICYCIVE THERAPEUTICS | 3,860 | -3,02 % | Unicycive Therapeutics, Inc.: Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease | LOS ALTOS, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the... ► Artikel lesen | |
| DYNE THERAPEUTICS | 13,170 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 52,50 | +3,20 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary | WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines... ► Artikel lesen |
OS THERAPIES INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 2,235 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OS THERAPIES INC finden Sie auf Wallstreet Online.